Gastrointestinal

Cirrhosis: outpatient management and complications surveillance

Clinical Overview and When to Suspect Cirrhosis

— ~2 million US adults have cirrhosis; rising due to MASLD (formerly NAFLD) and alcohol-associated liver disease (ALD)

— HCV burden declining with DAA treatment; HBV stable; MASLD and ALD now lead new diagnoses

— Abnormal LFTs persisting >6 months, especially AST:ALT >1 with thrombocytopenia

— Stigmata: spider angiomata, palmar erythema, splenomegaly, gynecomastia

— Incidental imaging: nodular liver contour, splenomegaly, recanalized umbilical vein, ascites

— Unexplained thrombocytopenia (<150K), low albumin, prolonged INR, or hyponatremia

— Compensated: no ascites, no variceal hemorrhage, no encephalopathy, no jaundice; median survival >12 years

— Decompensated: any of the above; median survival 2 years; triggers liver transplant evaluation

— Alcohol use disorder, MASLD/MASH, chronic HBV/HCV, hemochromatosis, Wilson disease, alpha-1 antitrypsin, autoimmune hepatitis, PBC, PSC, drug-induced

Definition: Cirrhosis is the end-stage of chronic liver injury characterized by diffuse fibrosis with regenerative nodule formation, distorting hepatic architecture and producing portal hypertension and hepatocellular dysfunction.

Epidemiology in US ambulatory practice:

When to suspect in clinic:

Compensated vs decompensated (a Step 3 framing pillar):

Etiologies to actively pursue (you must identify cause to direct management):

Step 3 management: When cirrhosis is newly suspected in outpatient clinic, order CBC, CMP, INR, hepatitis B surface antigen/surface antibody/core antibody, HCV antibody with reflex RNA, iron studies, ANA, ASMA, AMA, ceruloplasmin if <40, alpha-1 antitrypsin level, and abdominal ultrasound with Doppler at the index visit—do not piecemeal these across multiple visits, as etiology workup gates therapy and transplant listing.

Board pearl: Platelets <150,000 in a patient with chronic liver disease is the single most sensitive lab clue to cirrhosis—reflecting splenic sequestration from portal hypertension and reduced hepatic thrombopoietin.

Presentation Patterns and Key History

— Asymptomatic: incidental thrombocytopenia, abnormal LFTs, or imaging finding; most common today

— Subtle constitutional: fatigue, decreased exercise tolerance, mild RUQ discomfort, loss of libido, muscle wasting

— Decompensation event: new ascites with abdominal distention, hematemesis/melena from varices, confusion/sleep reversal from hepatic encephalopathy (HE), or jaundice

— Alcohol: quantify in standard drinks/day, duration, AUDIT-C score; ask in nonjudgmental way; >3 drinks/day women, >4 men confers risk

— Metabolic: BMI, T2DM, dyslipidemia, hypertension, OSA—drivers of MASH

— Viral exposures: IV drug use (even remote), tattoos pre-1992, blood transfusion before 1992, country of birth (HBV-endemic), sexual history

— Medications/supplements: methotrexate, amiodarone, isoniazid, herbal supplements (kava, comfrey, green tea extract)

— Family history: hemochromatosis (HFE C282Y), Wilson disease, alpha-1 antitrypsin, autoimmune disease

— Symptoms of decompensation: ankle swelling, abdominal girth changes, sleep-wake reversal, asterixis described by family, GI bleeding, pruritus, easy bruising

— Hematemesis, melena, or hematochezia → emergent variceal eval

— New confusion, slowed mentation, day/night reversal → HE workup with NH3 not required for diagnosis (clinical)

— Rapidly increasing abdominal girth with fever → SBP rule-out

— Pruritus + jaundice + fatigue in middle-aged woman → think PBC (AMA)

Three classic outpatient presentations:

Targeted history elements (every cirrhosis intake):

Red flag review of systems prompting urgent attention:

CCS pearl: On a CCS case with newly diagnosed cirrhosis, advance the clock to the first follow-up after ordering etiology labs and ultrasound; do not order EGD or HCC surveillance until cirrhosis is confirmed and patient is counseled.

Key distinction: Acute hepatitis with markedly elevated transaminases (>500) is usually not cirrhosis; cirrhosis classically shows modestly elevated or even normal AST/ALT with synthetic dysfunction (low albumin, elevated INR, low platelets).

Physical Exam Findings and Hemodynamic Assessment

— Spider angiomata (upper trunk, >3 highly suggestive), palmar erythema, Dupuytren contracture

— Scleral icterus when bilirubin >2.5–3 mg/dL; jaundice when >3

— Parotid enlargement and facial telangiectasias in ALD

— Kayser-Fleischer rings (slit lamp) in Wilson disease

— Gynecomastia, testicular atrophy from impaired estrogen clearance

— Caput medusae from recanalized periumbilical vein (portal HTN)

— Hepatomegaly early; small, nodular, firm liver late

— Splenomegaly (palpable tip in 30–40%)

— Ascites: shifting dullness (sensitivity ~80%), fluid wave (specific), umbilical hernia

— Asterixis: ask patient to extend wrists with fingers spread for 30 seconds; flapping = HE

— Constructional apraxia (cannot draw a star or copy figure)

— Number connection test prolonged in covert HE

— Fetor hepaticus (sweet, musty breath) in advanced HE

— Cirrhotics have hyperdynamic circulation: low SVR, high cardiac output, low-normal BP, warm extremities, bounding pulses

— Resting tachycardia common; relative hypotension (SBP <100) signals advanced disease and worse prognosis

— Concurrent volume overload (ascites/edema) with intravascular underfilling complicates diuretic dosing

— Temporal wasting, thenar atrophy, reduced grip strength

— Liver Frailty Index (grip, chair stands, balance) predicts mortality and transplant outcomes

Cutaneous and head/neck stigmata:

Chest/abdomen:

Neurologic:

Volume/hemodynamic assessment (outpatient framework):

Sarcopenia and frailty assessment:

Board pearl: A cirrhotic with SBP persistently <90 mmHg off vasoactive medications has a high 1-year mortality and should be evaluated for transplant; avoid nonselective beta-blockers if SBP <90 or serum Na <130, as they worsen circulatory dysfunction in advanced cirrhosis.

Step 3 management: Document Child-Pugh class and MELD 3.0 score at every visit—both drive prognosis, transplant priority, and procedure risk.

Diagnostic Workup — Initial Labs, Imaging, and Noninvasive Fibrosis

— CBC (platelets, anemia), CMP (Na, Cr, AST/ALT, alk phos, bilirubin, albumin), INR

— Calculate MELD 3.0 (bilirubin, INR, Cr, Na, albumin, sex) and Child-Pugh (bilirubin, albumin, INR, ascites, encephalopathy)

— HBsAg, anti-HBs, anti-HBc total; HCV Ab with reflex RNA

— Iron studies + ferritin (transferrin sat >45% → HFE gene testing)

— ANA, anti-smooth muscle Ab, IgG (autoimmune hepatitis)

— AMA, alk phos (PBC); MRCP if PSC suspected

— Ceruloplasmin (<20 mg/dL) and 24-hr urine copper in patients <40

— Alpha-1 antitrypsin level and phenotype

— HbA1c, lipid panel, metabolic workup for MASH

— Abdominal US with Doppler at diagnosis: confirms nodular liver, splenomegaly, ascites, portal vein patency; baseline for HCC surveillance

— Cross-sectional (CT or MRI) reserved for nodules, vascular complications, or pretransplant evaluation

— FIB-4 (age, AST, ALT, platelets): >2.67 suggests advanced fibrosis; <1.3 (or <2.0 if >65) rules it out

— APRI: alternative simple score

— Transient elastography (FibroScan): liver stiffness >12.5 kPa supports cirrhosis; <8 kPa makes it unlikely

— ELF test, MR elastography in select cases

Core labs every visit for known cirrhosis:

Initial etiology panel (if not yet done):

Imaging:

Noninvasive fibrosis assessment (use to stage and follow):

Why noninvasive matters in clinic: Liver biopsy is no longer required to diagnose cirrhosis when stigmata, imaging, and elastography align—reserve biopsy for diagnostic uncertainty or competing etiologies.

Key distinction: AST > ALT with ratio >2 suggests alcohol-associated liver disease; ALT > AST suggests viral or MASH. As cirrhosis progresses from any cause, AST surpasses ALT due to mitochondrial enzyme leakage and pyridoxine deficiency.

Board pearl: A FibroScan score of 20–25 kPa with platelets <150K predicts clinically significant portal hypertension (Baveno VII)—this patient needs EGD or capsule for variceal screening even if asymptomatic.

Diagnostic Workup — Confirmatory Studies and Portal Hypertension Assessment

— Indicated in all newly diagnosed cirrhosis unless Baveno VII criteria met for noninvasive exclusion (LSM <20 kPa AND platelets >150K—then EGD can be deferred)

— Repeat interval based on findings:

— No varices, compensated: every 2–3 years

— Small varices, no treatment: every 1–2 years

— Decompensation event: repeat at decompensation

— Gold standard for portal hypertension; >5 mmHg defines portal HTN, ≥10 clinically significant, ≥12 risk of variceal bleeding

— Performed at referral centers; informs nonselective beta-blocker (NSBB) response, TIPS candidacy, prognosis

— Abdominal US ± AFP every 6 months for all cirrhotics regardless of etiology

— Also screen non-cirrhotic HBV in select groups (Asian men >40, women >50, African >20, family history of HCC)

— Any nodule >1 cm → multiphase CT or MRI with LI-RADS classification

— Indicated when noninvasive testing inconclusive, overlap syndromes (AIH-PBC), suspected drug-induced, or to grade necroinflammation

— Transjugular route preferred if ascites or coagulopathy (allows simultaneous HVPG)

— Echocardiogram with bubble study (HPS), DLCO, right heart cath if PoPH suspected

— Bone density, age-appropriate cancer screening, dental clearance

— Psychosocial evaluation, alcohol/substance use assessment with 6-month sobriety documentation in many centers (though strict rule increasingly relaxed)

EGD for variceal screening:

HVPG (hepatic venous pressure gradient):

HCC surveillance (must implement at diagnosis):

Liver biopsy (selective use):

Pretransplant workup triggers (refer when MELD ≥15 or first decompensation):

Step 3 management: A 58-year-old with newly diagnosed compensated cirrhosis needs—at the index visit or shortly after—(1) etiology labs, (2) abdominal US baseline + q6mo HCC surveillance, (3) EGD or noninvasive Baveno assessment, (4) vaccination update, (5) MELD/Child-Pugh calculation, (6) hepatology referral if decompensated or MELD ≥10.

CCS pearl: Order HCC surveillance ultrasound on a recurring 6-month basis—forgetting this is a common CCS scoring miss.

Risk Stratification and Management Logic

— Child-Pugh A (5–6): well compensated, 1-yr survival ~100%

— Child-Pugh B (7–9): significant compensation challenge, 1-yr ~80%

— Child-Pugh C (10–15): decompensated, 1-yr ~45%

— MELD 3.0: drives transplant allocation; ≥15 = transplant benefit exceeds risk

— LSM <10 kPa rules out cACLD

— LSM 10–15: gray zone, repeat testing

— LSM ≥15 plus platelets <150K: clinically significant portal HTN highly likely → start NSBB for primary prevention of decompensation

1. Treat the etiology: DAAs for HCV, tenofovir/entecavir for HBV, alcohol abstinence, weight loss for MASH, phlebotomy for hemochromatosis, urso for PBC

2. Surveillance: HCC US q6mo, variceal screening per protocol

3. Vaccinate: HAV, HBV (if non-immune), annual influenza, pneumococcal (PCV20 or PCV15+PPSV23), COVID, Tdap, zoster, RSV if eligible

4. Prevent decompensation: NSBB if CSPH; avoid hepatotoxins, NSAIDs, aminoglycosides; sodium restriction <2 g/day if ascites

5. Optimize nutrition and frailty: 1.2–1.5 g/kg protein, late-evening snack, address sarcopenia

— Stop NSAIDs (AKI, variceal bleeding), avoid ACEi/ARB in advanced disease with low SBP, careful sedatives/opioids (HE risk), reduce or avoid statins only if Child-Pugh C (low-dose statins are otherwise safe and beneficial)

Stratification frameworks:

Baveno VII compensated advanced chronic liver disease (cACLD) staging:

Five outpatient pillars for every cirrhotic (Step 3 framework):

Medication review at every visit (deprescribing focus):

Key distinction: Compensated cirrhosis is largely managed by primary care/GI; decompensated cirrhosis warrants hepatology referral and transplant evaluation—do not delay referral waiting for sobriety milestones, as listing can occur in parallel.

Board pearl: Statins are safe and likely beneficial (reduce decompensation and HCC) in Child-Pugh A and B cirrhosis; reserve avoidance for Child-Pugh C or when CK rises.

Pharmacotherapy — First-Line Outpatient Regimens

— Carvedilol 6.25 mg daily, titrate to 12.5 mg (preferred—better HVPG reduction)

— Alternative: propranolol 20 mg BID titrated, or nadolol 20–40 mg daily

— Indications: CSPH (LSM ≥25 kPa or HVPG ≥10), small varices with high-risk features, any medium/large varices (primary prophylaxis), or post-bleed secondary prophylaxis

— Target: HR 55–60 or maximally tolerated; or HVPG reduction ≥20% / <12 mmHg

— Hold/discontinue if: SBP <90, Na <130, AKI, SBP episode, or refractory ascites with hypotension

— Spironolactone 100 mg + furosemide 40 mg PO daily (100:40 ratio preserves K)

— Titrate every 3–5 days to max 400:160; goal weight loss 0.5 kg/day (no edema) or 1 kg/day (with edema)

— Monitor Na, K, Cr weekly initially; stop if Na <125, Cr rising >0.3, or HE

— 15–30 mL TID-QID titrated to 2–3 soft stools daily

— Add rifaximin 550 mg BID after first overt HE episode for secondary prevention (reduces recurrence by ~50%)

— HBV: tenofovir alafenamide or entecavir indefinitely if cirrhosis (regardless of DNA level)

— HCV: pan-genotypic DAA (glecaprevir-pibrentasvir or sofosbuvir-velpatasvir)—even decompensated benefit, but avoid protease inhibitors in Child-Pugh B/C

— AIH: prednisone ± azathioprine

— PBC: ursodeoxycholic acid 13–15 mg/kg/day; add obeticholic acid or fibrates if inadequate response (avoid OCA in decompensated)

— Hemochromatosis: therapeutic phlebotomy to ferritin <50

— Wilson: penicillamine or trientine + zinc

— MASH: weight loss 7–10%, GLP-1 RA, resmetirom (FDA-approved 2024) for F2–F3, but not in decompensated cirrhosis

— Large-volume paracentesis (>5 L): 6–8 g albumin per liter removed

— Long-term albumin (ANSWER trial) considered in select refractory ascites

Nonselective beta-blockers (NSBB) for portal hypertension:

Diuretics for ascites:

Lactulose for HE:

Etiology-specific therapy:

Albumin (outpatient adjunct):

Step 3 management: When initiating spironolactone/furosemide for ascites, schedule a basic metabolic panel in 5–7 days, then weekly until stable—do not just see them in a month; CCS clocks should reflect this cadence.

Procedures and Invasive Management

— Diagnostic: at every new ascites presentation and at every hospitalization to rule out SBP (PMN ≥250 cells/mm³ = treat)

— Therapeutic LVP: for tense or refractory ascites; replace with albumin 6–8 g/L removed when >5 L

— Outpatient cadence: every 1–2 weeks for refractory ascites

— Variceal band ligation (EVL) every 2–4 weeks until eradication, then surveillance EGD at 3–6 months, then annually

— Acute bleed: EVL + IV octreotide 50 mcg bolus then 50 mcg/hr × 3–5 days + ceftriaxone 1 g IV × 7 days

— Indications: refractory ascites, recurrent variceal bleeding despite EVL+NSBB, early/preemptive TIPS within 72 hr of acute variceal bleed in Child-Pugh B with active bleeding or Child-Pugh C (<14)

— Contraindications: Child-Pugh C >13, MELD >18 (relative), severe pulmonary HTN, right heart failure, uncontrolled sepsis, biliary obstruction

— Complications: HE (~30%), shunt stenosis, worsening liver function

— Refer at MELD ≥15, first decompensation, HCC within Milan criteria (1 lesion ≤5 cm or up to 3 lesions ≤3 cm), or refractory complications

— Living donor and split-graft options expanding

— Splenic artery embolization for refractory thrombocytopenia (rare)

— Tunneled peritoneal catheter (PleurX) for palliative ascites

— TACE/Y-90/ablation for HCC bridging

— Umbilical hernias common with ascites; control ascites first before elective repair; emergent repair only if incarcerated/ruptured

Paracentesis:

Endoscopic variceal management:

TIPS (transjugular intrahepatic portosystemic shunt):

Liver transplantation:

Adjunctive procedures:

Hernia management:

CCS pearl: For a patient on the ward with new ascites, the diagnostic paracentesis is mandatory at admission—forgetting it delays SBP diagnosis and is a frequent scoring penalty. Send cell count + differential, culture in blood culture bottles at bedside, albumin, total protein, and gram stain.

Board pearl: A SAAG ≥1.1 g/dL confirms portal hypertensive ascites; <1.1 suggests peritoneal carcinomatosis, TB, or pancreatic ascites.

Special Populations — Elderly and Renal/Hepatic Considerations

— Higher prevalence of MASH and HCV (birth cohort 1945–1965)

— Polypharmacy increases hepatotoxin and sedative exposure—review meds at every visit

— Lower threshold for HE from constipation, dehydration, infection

— Frailty drives transplant outcomes more than age alone; selected patients into their 70s transplanted successfully

— AKI definition: Cr increase ≥0.3 mg/dL within 48 hr or ≥50% from baseline

— Three categories:

— Prerenal/volume responsive: diuretic overuse, GI bleed, lactulose-induced diarrhea—hold diuretics, give albumin 1 g/kg × 2 days

— Hepatorenal syndrome–AKI (HRS-AKI): no improvement after albumin + diuretic hold, no shock/nephrotoxin, no structural disease

— Intrinsic ATN or obstruction

— HRS-AKI treatment: terlipressin (FDA-approved 2022) + albumin; alternatives norepinephrine + albumin in ICU or midodrine + octreotide + albumin

— Avoid: NSAIDs (renal, bleeding), aminoglycosides, high-dose acetaminophen (>2 g/day), metformin only stop if decompensated/AKI, sulfonylureas with caution

— Reduce: opioids (use low-dose hydromorphone or fentanyl), benzodiazepines (if needed, oxazepam/lorazepam/temazepam—no hepatic phase I metabolism)

— Safer: acetaminophen ≤2 g/day for pain (preferred over NSAIDs), low-dose statins, SSRIs with caution

— Cirrhosis is not auto-protective against thrombosis; portal vein thrombosis and DVT/PE occur

— Apixaban preferred in Child-Pugh A–B; avoid DOACs in Child-Pugh C; warfarin difficult due to baseline INR elevation

Elderly cirrhotics:

Renal dysfunction in cirrhosis (critical to recognize):

Drug dosing in hepatic impairment:

Anticoagulation:

Key distinction: Baseline INR elevation in cirrhosis reflects impaired synthesis of both pro- and anticoagulants—it does not equate to "auto-anticoagulation." Do not use INR to gauge bleeding risk or to withhold prophylactic anticoagulation.

Step 3 management: New AKI in a cirrhotic outpatient → hold diuretics and NSBB, hold nephrotoxins, recheck Cr at 48 hr, and arrange urgent labs/albumin challenge; if Cr does not improve, admit for HRS workup.

Special Populations — Pregnancy, Pediatrics, and Other Subgroups

— Rare but increasing with MASH; preconception counseling essential

— Higher risk of variceal bleeding (peaks 2nd trimester), preeclampsia, IUGR, preterm birth, maternal/fetal mortality

— EGD in 2nd trimester for variceal screening; band ligation safe if needed

— Avoid NSBB only if growth restriction concerns; carvedilol/propranolol generally continued

— Avoid: ribavirin (teratogenic—wait 6 months post-DAA), MMF, methotrexate

— Safer: tenofovir for HBV (also reduces vertical transmission if HBV DNA >200,000 IU/mL in 3rd trimester), urso for PBC, azathioprine for AIH

— Wilson disease, alpha-1 antitrypsin, autoimmune hepatitis, biliary atresia—pursue genetic causes early

— MASH increasingly diagnosed in adolescents with obesity

— Abstinence is the single most impactful intervention—even Child-Pugh C can recompensate

— Pharmacotherapy: baclofen preferred (hepatically safe); naltrexone avoided in active liver injury; acamprosate ok if eGFR adequate

— Behavioral: motivational interviewing, AA, intensive outpatient programs

— Update MELD frequently per UNOS schedule

— Exception points for HCC within Milan, hepatopulmonary syndrome (PaO2 <60), portopulmonary HTN (treated MPAP <35)

— Accelerated fibrosis; treat HBV/HCV aggressively; coordinate ART for hepatic safety

— Cirrhosis disproportionately affects Hispanic and Native American populations (higher MASH and ALD); rural patients have worse HCC outcomes

— Ensure HCC surveillance reminders, patient navigator referral, telehepatology when geography limits access

Pregnancy with cirrhosis:

Pediatric and young adult considerations:

Alcohol use disorder cohort:

Patients listed for transplant:

Patients with HIV coinfection:

Underserved/health systems lens:

Board pearl: Pregnancy in a known cirrhotic mandates a multidisciplinary plan: MFM + hepatology + anesthesia. Vaginal delivery with assisted second stage (avoid Valsalva that increases variceal pressure) is generally preferred; C-section for obstetric indications only.

CCS pearl: HBV+ pregnant patient with DNA >200,000 IU/mL → start tenofovir at 28 weeks and give infant HBIG + vaccine at birth.

Complications and Adverse Outcomes

— Uncomplicated → sodium restriction + diuretics

— Refractory → LVP, TIPS, transplant evaluation

— Hepatic hydrothorax: pleural effusion (usually right) from diaphragmatic defects; manage like ascites; avoid chest tubes (high mortality)

— Ascitic PMN ≥250/mm³; treat empirically with ceftriaxone 2 g IV daily × 5 days

— Give albumin 1.5 g/kg day 1, 1 g/kg day 3 if Cr >1, BUN >30, or bilirubin >4 (reduces HRS, mortality)

— Secondary prophylaxis: lifelong ciprofloxacin 500 mg daily or TMP-SMX

— Primary prophylaxis if ascitic protein <1.5 with Na ≤130, Cr ≥1.2, or bilirubin ≥3

— Mortality 15–20% per bleed; prevent with NSBB and/or EVL

— Precipitants: infection (SBP!), GI bleed, constipation, dehydration, sedatives, hyponatremia, TIPS, hypokalemia

— Treat precipitant + lactulose ± rifaximin

— Annual incidence 1–4% in cirrhosis; surveillance US ± AFP q6mo

— Triad: liver disease + hypoxemia (A-a gradient ≥15) + intrapulmonary shunting (positive bubble echo)

— Platypnea-orthodeoxia (worse upright); only cure is transplant; MELD exception if PaO2 <60

— Right heart cath: mPAP >25, PVR >3 Wood, PCWP <15

— Treat with PDE5 inhibitors or ERAs; mPAP must be <35 to list for transplant

Ascites (most common decompensation):

Spontaneous bacterial peritonitis (SBP):

Variceal hemorrhage:

Hepatic encephalopathy:

Hepatorenal syndrome: see chunk 9

Hepatocellular carcinoma:

Hepatopulmonary syndrome (HPS):

Portopulmonary hypertension (PoPH):

Cirrhotic cardiomyopathy: blunted contractile response to stress, diastolic dysfunction, prolonged QT

Coagulopathy and infection: rebalanced hemostasis with both bleeding and clotting risk; immune dysfunction increases bacterial infections

Adrenal insufficiency: relative AI common in severe disease

Key distinction: New confusion in a cirrhotic is HE only after ruling out infection, GI bleed, electrolyte derangement, and intracranial event—don't anchor on lactulose alone.

Board pearl: After first SBP, 1-year recurrence is ~70% without prophylaxis—lifelong fluoroquinolone prophylaxis is standard.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Active GI bleeding (hematemesis, melena, hematochezia) regardless of hemodynamics

— Altered mental status / overt HE grade ≥2 not safely manageable at home

— Fever with ascites (assume SBP until proven otherwise)

— New jaundice with rising Cr (concern for HRS or acute-on-chronic liver failure)

— Hypotension SBP <90 or rapid weight loss with AKI

— Severe hyponatremia <125 or symptomatic

— Variceal bleed with shock or transfusion requirement

— Grade 3–4 HE (somnolence, coma) needing airway protection

— HRS-AKI requiring terlipressin (some centers monitor on telemetry/ICU)

— Sepsis with shock or lactate >4

— Acute-on-chronic liver failure (ACLF) by EASL-CLIF criteria (organ failures)

— Hepatology: first decompensation, MELD ≥10, transplant candidacy, complex etiology

— GI: EGD for variceal screening/banding

— Interventional radiology: TIPS, paracentesis when difficult, TACE for HCC

— Transplant surgery: MELD ≥15 or HCC

— Palliative care: refractory symptoms, decompensated and not transplant candidate

— Addiction medicine: AUD with cirrhosis benefits from co-management

— Acute decompensation + organ failure(s) in chronic liver disease

— Mortality 30–80% at 28 days depending on grade

— Often precipitated by infection, alcohol bingeing, drug-induced injury, HBV reactivation, ischemic injury

— Aggressive ICU care + rule out reversible triggers + expedited transplant evaluation

Immediate ED/inpatient transfer from clinic:

ICU triggers:

Specialty consultations:

ACLF concept (Step 3 high yield):

Step 3 management: A cirrhotic clinic patient with new fever and ascites → do not start empiric oral antibiotics and send home; admit, paracentesis with cell count, start IV ceftriaxone, and give albumin. This is one of the highest-yield CCS sequences.

CCS pearl: Outpatient management is appropriate for grade 1 HE with reliable home support, stable vitals, mild ascites, no infection signs, and ability to follow up in 48–72 hr.

Key Differentials — Same-Category (Hepatic) Causes

— Acute: AST/ALT >500, recent onset, may have INR elevation but no thrombocytopenia or stigmata

— Cirrhosis: modest AST/ALT, thrombocytopenia, splenomegaly, low albumin, stigmata

— Causes: portal vein thrombosis, schistosomiasis (worldwide #1 cause of portal HTN), nodular regenerative hyperplasia, idiopathic

— Liver synthetic function preserved; varices and splenomegaly present

— Distinguish with imaging (vascular), elastography (often <12 kPa), biopsy

— Hepatic vein thrombosis; presents with painful hepatomegaly, ascites, often with underlying myeloproliferative disease (JAK2)

— Doppler US shows absent/reversed hepatic vein flow

— Right heart failure, constrictive pericarditis, severe tricuspid regurgitation

— Pulsatile liver, elevated JVP, ascites with SAAG ≥1.1 AND total protein ≥2.5 (cirrhosis has protein <2.5)

— INR ≥1.5 + encephalopathy within 26 weeks in previously healthy liver

— Acetaminophen, viral, drug, autoimmune, Wilson disease

— Different management: transfer to transplant center, N-acetylcysteine

Acute hepatitis vs cirrhosis:

Noncirrhotic portal hypertension:

Budd-Chiari syndrome:

Congestive hepatopathy:

Fulminant hepatic failure / acute liver failure:

Cholestatic liver diseases without cirrhosis: PBC, PSC, drug-induced cholestasis—may progress to cirrhosis but earlier stages distinct

Granulomatous hepatitis: sarcoidosis, TB, drugs

Infiltrative diseases: amyloidosis, lymphoma—elastography may show stiffness without true cirrhosis architecture

Key distinction: Ascitic fluid total protein ≥2.5 g/dL with SAAG ≥1.1 suggests cardiac ascites; <2.5 with SAAG ≥1.1 suggests cirrhotic ascites. This single bedside differential separates two very different management algorithms.

Board pearl: A young patient with new ascites, hepatomegaly, and abdominal pain → think Budd-Chiari; check for JAK2 V617F mutation and Doppler ultrasound urgently.

Key Differentials — Non-Hepatic Causes of Overlapping Findings

— Peritoneal carcinomatosis: SAAG <1.1, high LDH, malignant cells on cytology; ovarian, gastric, pancreatic, colon primaries

— TB peritonitis: high lymphocyte count, ADA elevated, foreign-born or HIV

— Nephrotic syndrome: anasarca, proteinuria >3.5 g/day, SAAG <1.1

— Pancreatic ascites: high amylase in fluid

— Myxedema ascites: severe hypothyroidism, high protein, SAAG variable

— ITP, drug-induced (HIT, valproate), bone marrow disorders, hypersplenism from other causes (sarcoid, Gaucher)

— Distinguish with smear, B12/folate, marrow if needed

— Uremic encephalopathy, hypoglycemia, electrolyte (hyponatremia, hypercalcemia), hypoxia, hypercapnia, Wernicke (especially alcoholics—always give thiamine before glucose), drug intoxication, infection (meningitis, UTI), intracranial hemorrhage (low threshold for CT in coagulopathic faller), nonconvulsive status epilepticus

— Heart failure, nephrotic syndrome, protein-losing enteropathy, lymphedema, medication-induced (CCBs, gabapentin)

— Hemolysis (indirect hyperbilirubinemia, elevated LDH, low haptoglobin)

— Gilbert syndrome (mild unconjugated, fasting/illness, otherwise normal)

— Biliary obstruction (dilated ducts on US, elevated alk phos out of proportion)

— Sepsis-induced cholestasis

Ascites mimics:

Thrombocytopenia mimics:

Encephalopathy mimics:

Edema/anasarca mimics:

Jaundice mimics:

Spider angiomata/palmar erythema can occur in pregnancy, thyrotoxicosis, normal variants—context matters

Key distinction: Wernicke encephalopathy and HE both occur in alcohol use—ophthalmoplegia and ataxia point to Wernicke; asterixis and elevated NH3 point to HE. Give IV thiamine empirically to any alcoholic with altered mentation before glucose to prevent precipitating Wernicke.

Step 3 management: Anasarca with low albumin → check urine protein/Cr ratio; do not anchor on cirrhosis if portal stigmata are absent.

Secondary Prevention, Discharge Meds, and Long-Term Plan

— Hepatitis A and B series if not immune

— Annual influenza

— Pneumococcal: PCV20 alone, or PCV15 followed by PPSV23

— Tdap, COVID-19 (current strain), zoster (recombinant) ≥50, RSV ≥60

— HCC: US ± AFP q6mo lifelong

— Age-appropriate: colon, breast, cervical, prostate, lung as guidelines indicate

— DEXA at diagnosis especially in PBC/PSC and chronic steroid users

— Calcium 1200 mg, vitamin D 800–1000 IU; bisphosphonates if osteoporosis (use oral with caution in varices; consider IV)

— Alcohol: complete abstinence; referral to AUD treatment

— Diet: 1.2–1.5 g/kg protein (do not restrict for HE—worsens sarcopenia), sodium <2 g/day if ascites, fluid restrict only if Na <125

— Late-evening carbohydrate snack reduces overnight gluconeogenesis from muscle

— Coffee 2–3 cups/day associated with reduced fibrosis progression

After SBP: lifelong ciprofloxacin 500 mg daily or norfloxacin 400 mg daily (or TMP-SMX if quinolone intolerance)

After variceal bleed: NSBB (carvedilol or nadolol) + serial EVL until eradication + PPI short course post-banding; consider TIPS for early rebleed

After first overt HE: lactulose + rifaximin 550 mg BID indefinitely; counsel family on triggers, prescribe stool log, ensure access to lactulose refills

Vaccinations (verify and document yearly):

Cancer surveillance:

Bone health:

Lifestyle and nutrition:

Medication safety card: list of agents to avoid (NSAIDs, aminoglycosides, high-dose acetaminophen, herbals)

Advance care planning: discuss goals of care, code status, transplant willingness, surrogate decision-maker

Step 3 management: At every cirrhosis follow-up, document 5-point checklist: (1) decompensation symptoms, (2) MELD/Child-Pugh, (3) HCC surveillance status, (4) variceal status and NSBB, (5) vaccinations and AUD support. This mirrors the structure of board vignette stems.

Board pearl: Coffee (caffeinated, 2–3 cups/day) is one of few "lifestyle" interventions with consistent evidence for reduced progression and HCC risk in cirrhosis.

Follow-Up, Monitoring Parameters, and Counseling

— Compensated Child-Pugh A: every 6 months with US + AFP

— Compensated Child-Pugh B / decompensated: every 3 months minimum, more often if titrating diuretics/NSBB

— After hospital discharge for decompensation: clinic within 7–14 days, with labs (CMP, INR, CBC) at that visit

— After paracentesis or banding: within 1–2 weeks

— CBC, CMP, INR, MELD calculation

— Diuretic safety panel within 5–7 days of any titration

— HBV DNA and ALT q3–6 months on antivirals; HCV cure SVR12 confirmed once

— AFP q6mo with US

— Alcohol abstinence (every visit, brief intervention, refer to treatment); document with AUDIT-C

— Weight loss for MASH: 5% improves steatosis, 7–10% improves fibrosis

— Medication safety: NSAIDs, herbal supplements

— Sodium restriction for ascites with practical handouts

— Driving safety with HE history (covert HE impairs reaction time—some states require reporting)

— Sick-day plan: when to call, when to come to ED

— Refer to pulmonary/cardiac/cirrhosis-specific rehab where available

— Resistance training 2–3×/week reduces sarcopenia

— Liver Frailty Index tracked over time

— Depression and anxiety common; SSRIs generally safe (sertraline, escitalopram preferred)

— Screen for suicidality, especially after diagnosis or decompensation

— Keep listed patients up to date on dental, cardiac, infectious clearances

— Address modifiable contraindications (active substance use, untreated infection)

Visit cadence:

Monitoring labs at each visit:

Counseling priorities:

Rehabilitation/frailty:

Mental health:

Transplant readiness maintenance:

CCS pearl: After admission for SBP, the 7–14 day post-discharge clinic visit is a frequent CCS scoring point—do not advance the clock 30 days. Check labs, confirm prophylaxis started, review symptoms.

Key distinction: Covert HE (subclinical) impairs driving and work performance even when patients appear normal—use psychometric or computerized testing in occupational decisions.

Ethical, Legal, and Patient Safety Considerations

— Historic 6-month abstinence rule for ALD is being abandoned in favor of individualized psychosocial assessment; early liver transplant for severe alcoholic hepatitis with first lifetime presentation now offered at many centers

— Avoid bias: insurance status, language, socioeconomic factors should not block referral

— Patients with overt or covert HE may lack capacity for complex decisions—reassess after HE treatment before consenting for TIPS, transplant, or major surgery

— Document capacity assessment using clear criteria (understanding, appreciation, reasoning, communicating choice)

— Identify surrogate early; encourage advance directives at diagnosis

— Covert HE impairs reaction time and judgment; counsel on driving cessation during episodes and consider formal testing for high-risk occupations (commercial drivers, pilots)

— Some jurisdictions require physician reporting for impaired driving—know local law

— Acute viral hepatitis (A, B, C) is reportable in all states

— Suspected hepatotoxin exposure (occupational) reporting per state

— 42 CFR Part 2 protects substance use treatment records—obtain specific consent for release; matters when coordinating with transplant centers

— Medication reconciliation after every hospitalization—particularly diuretic doses, lactulose, rifaximin, NSBB

— Ensure prescriptions filled (call pharmacy if needed), patient understands sliding scale, has scale at home for weight monitoring

— Schedule follow-up before discharge, not after; provide direct hepatology contact

— Avoid sending home with new opioid or benzodiazepine prescriptions

— Decompensated cirrhosis not eligible for transplant has prognosis comparable to advanced cancer—palliative referral underused

— Address symptom management (pruritus, cramps, ascites), hospice eligibility (Child-Pugh C, refractory complications)

Transplant listing equity:

Informed consent edge cases:

Driving and public safety:

Mandatory reporting:

Alcohol use disorder confidentiality:

Transitions of care safety (Step 3 emphasis):

End-of-life and palliative care:

Step 3 management: A patient with refractory ascites and HE who refuses transplant evaluation despite full capacity should have decision documented after a values-based discussion; autonomy is preserved, and palliative care should be offered.

Board pearl: Never prescribe benzodiazepines for sleep or anxiety in a cirrhotic—high risk of precipitating HE; use trazodone or non-pharmacologic approaches.

High-Yield Associations and Rapid-Fire Clinical Facts

AST:ALT >2 → alcohol-associated liver disease

Spider angiomata >3 + palmar erythema + thrombocytopenia → cirrhosis until proven otherwise

SAAG ≥1.1 → portal hypertensive ascites; <1.1 → not portal HTN (carcinomatosis, TB, nephrotic, pancreatic)

Ascitic PMN ≥250 → SBP, treat with ceftriaxone + albumin

Ascitic protein ≥2.5 + SAAG ≥1.1 → cardiac ascites

Carvedilol > propranolol for portal HTN in modern algorithms

Terlipressin + albumin is first-line for HRS-AKI

MELD 3.0 uses sex, Na, albumin in addition to Cr/bilirubin/INR

Milan criteria for HCC transplant: 1 lesion ≤5 cm or up to 3 lesions ≤3 cm, no vascular invasion

HCC surveillance: US ± AFP every 6 months

Kayser-Fleischer ring + low ceruloplasmin → Wilson disease

AMA positive + alk phos elevated + middle-aged woman + pruritus → PBC; treat with urso

Bead-on-string cholangiogram + IBD → PSC; high colon cancer risk

HFE C282Y homozygote + transferrin sat >45% → hereditary hemochromatosis; phlebotomy

Alpha-1 antitrypsin → low level + PiZZ phenotype + emphysema

Hepatopulmonary syndrome triad: liver disease + hypoxemia + intrapulmonary shunt (bubble echo)

Portopulmonary HTN: mPAP >25 on right heart cath in a cirrhotic

Rifaximin prevents recurrent HE after first overt episode

Lactulose titrated to 2–3 soft stools daily

Coffee 2–3 cups/day, statins (in compensated), and weight loss reduce decompensation

Avoid: NSAIDs, aminoglycosides, benzodiazepines, high-dose acetaminophen >2 g/day, herbal supplements

Vaccinate: HAV, HBV, flu, pneumococcal, COVID, Tdap, zoster, RSV

Schistosomiasis = worldwide #1 cause of portal HTN; not cirrhosis but presinusoidal

Board pearl: A platelet count >150,000 with LSM <20 kPa in compensated cirrhosis (Baveno VII) allows deferral of screening EGD—a high-yield update many older review books miss.

Key distinction: Hyponatremia in cirrhosis is dilutional (excess ADH); treat by water restriction, not saline; tolvaptan only short term and not for routine use.

Board Question Stem Patterns

— 55-year-old with HTN noted to have platelets 120K, mild AST/ALT elevation, BMI 34. Next step? → MASH workup, FIB-4 calculation, US ± elastography, full etiology panel, vaccinate, schedule HCC surveillance if cirrhosis confirmed.

— New abdominal distention, ankle edema, BMI dropped, mild jaundice. Paracentesis shows SAAG 1.4, protein 1.0, PMN 100. → Diagnostic = uncomplicated cirrhotic ascites; start spironolactone + furosemide, sodium restriction, refer hepatology, start NSBB if not already.

— Cirrhotic with fever 38.3, abdominal pain, paracentesis PMN 450. → SBP; ceftriaxone 2 g IV daily × 5 days + albumin 1.5 g/kg day 1, 1 g/kg day 3; secondary prophylaxis with ciprofloxacin afterward.

— Cirrhotic on diuretics develops Cr from 0.9 → 1.8, UNa <10, bland sediment, no shock, no response to diuretic hold + albumin 1 g/kg × 2 days. → HRS-AKI; terlipressin + albumin.

— Cirrhotic brought in with somnolence, asterixis, recent constipation. Rule out GI bleed, infection (SBP!), electrolytes, glucose. Treat with lactulose; add rifaximin for prevention.

— Hematemesis, hypotension. IV access × 2, fluid resuscitation, transfuse to Hb 7, octreotide, ceftriaxone, EGD with banding within 12 hr, restrictive transfusion strategy.

— Surveillance US shows 2-cm lesion. → Multiphase CT or MRI with LI-RADS; LR-5 lesion within Milan → transplant or resection if Child-Pugh A.

— Stem mentions ibuprofen for arthritis or alprazolam for sleep in a cirrhotic. → Discontinue and substitute (acetaminophen ≤2 g/day, trazodone).

— Cirrhotic presents for annual visit; ask which vaccines are needed (HAV, HBV, pneumococcal, influenza).

Stem 1 — The incidental finding:

Stem 2 — The first decompensation:

Stem 3 — Fever + ascites:

Stem 4 — Rising creatinine:

Stem 5 — Confusion:

Stem 6 — Variceal bleed:

Stem 7 — HCC:

Stem 8 — Drug to avoid:

Stem 9 — Vaccine miss:

CCS pearl: Most cirrhosis CCS cases test the bundle: order labs, ultrasound, EGD, vaccinations, MELD calculation, NSBB if indicated, HCC surveillance every 6 months, and schedule appropriate follow-up. Forgetting any single bundle element loses points.

Step 3 management: When a stem asks "next best step" after first decompensation, the answer is almost always refer for transplant evaluation in parallel with treating the acute complication.

One-Line Recap

Cirrhosis outpatient management hinges on identifying and treating the etiology, surveilling for HCC and varices every 6 months and per Baveno VII, preventing and treating each decompensation (ascites, SBP, variceal bleed, HE, HRS) with evidence-based bundles, and referring for transplant at first decompensation or MELD ≥15.

Five outpatient pillars: treat etiology, surveil (HCC US q6mo, varices per Baveno), vaccinate (HAV/HBV/flu/pneumo/COVID/Tdap/zoster/RSV), prevent decompensation (NSBB if CSPH, avoid hepatotoxins, sodium restriction), and optimize nutrition/frailty (1.2–1.5 g/kg protein, evening snack, resistance training).

High-yield decompensation algorithm: ascites → spironolactone/furosemide 100:40 + Na restriction; SBP → ceftriaxone + albumin + lifelong cipro; variceal bleed → octreotide + ceftriaxone + EVL + carvedilol; HE → lactulose + rifaximin after first episode; HRS-AKI → terlipressin + albumin.

Referral triggers: MELD ≥15, first decompensation event, HCC within Milan, refractory ascites, recurrent variceal bleeding, HPS (PaO2 <60), PoPH (treated mPAP <35), ACLF—refer hepatology and transplant early and in parallel, not sequentially.

Safety must-knows: avoid NSAIDs, aminoglycosides, benzodiazepines, high-dose acetaminophen >2 g/day, herbal supplements; capacity reassessment after HE before consent; covert HE impairs driving; statins and coffee are protective; post-discharge clinic in 7–14 days with labs is a CCS scoring linchpin.

Board pearl: The single most exam-relevant transition is from compensated to decompensated cirrhosis—the moment a patient develops ascites, varices that bleed, encephalopathy, or jaundice, the management paradigm shifts to bundles, prophylaxis, and transplant evaluation. Recognizing that pivot is the core of Step 3 cirrhosis questions.